Krajewski et al., 1995 - Google Patents
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic …Krajewski et al., 1995
View PDF- Document ID
- 4551316536822298349
- Author
- Krajewski S
- Blomqvist C
- Franssila K
- Krajewska M
- Wasenius V
- Niskanen E
- Nordling S
- Reed J
- Publication year
- Publication venue
- Cancer research
External Links
Snippet
Bax is a homologue of Bcl-2 that promotes apoptosis. Bax protein levels were assessed by immunohistochemical methods in primary tumors derived from 119 women with metastatic breast cancer. These patients had received combination chemotherapy either with a once a …
- 230000004044 response 0 title abstract description 39
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Krajewski et al. | Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma | |
Miyake et al. | Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer | |
Hsu et al. | Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence | |
Chan et al. | Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. | |
US6972170B1 (en) | Markers for prostate cancer | |
Mueller et al. | Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the long-term survival of memory cells. | |
Vargas‐Roig et al. | Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy | |
Sehgal et al. | Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro | |
KR20190015408A (en) | Anti-PD-1 antibody for use in methods of treating tumors | |
CN112972675A (en) | Use of anti-PD-1 antibodies in the treatment of tumors | |
Choi et al. | The regulation of apoptosis by activin and transforming growth factor-β in early neoplastic and tumorigenic ovarian surface epithelium | |
US20220193193A1 (en) | Methods for identification, assessment, prevention, and treatment of metabolic disorders using slit2 | |
Treish et al. | Pharmacology and therapeutic use of trastuzumab in breast cancer | |
US7244565B2 (en) | Gene shinc-3 and diagnostic and therapeutic uses thereof | |
US7348418B2 (en) | Carcinoma-related genes and polypeptides and methods of use thereof | |
Arends et al. | Gastrointestinal cancer‐associated antigen (GICA) immunoreactivity in colorectal carcinoma in relation to patient survival | |
KR102645036B1 (en) | Composition for diagnosing anti-cancer medicine resistance and kit comprising the same | |
Scott et al. | Genes mediating programmed cell death: an immunohistochemical study of bcl-2, c-myc and p53 expression in colorectal neoplasia | |
Hill et al. | Identification of a distinctive p‐glycoprotein‐mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated x‐irradiation | |
KR20170082537A (en) | Predicting response to a vegf antagonist | |
WO2014017106A1 (en) | Compositions Comprising RAC Mutants, and Methods of Use Thereof | |
Oda et al. | Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas | |
EP3460476B1 (en) | Biomarker composition comprising lrp-1 as active ingredient, for diagnosis of radiation-resistant cancer or prediction of radiation therapy prognosis | |
US20070106065A1 (en) | TAT- 001 and methods of assessing and treating cancer | |
Matias‐Guiu et al. | Expression of the ret proto‐oncogene in phaeochromocytoma. An in situ hybridization and northern blot study |